Genflow Biosciences PLC has provided an update on its animal health program, focusing on its GF-1004 clinical trial. The trial is evaluating the safety and efficacy of GF-1004, a gene therapy based on the SIRT6 variant found in centenarians, aimed at addressing age-related decline in elderly dogs.
The ongoing randomized, controlled trial involves 28 beagles aged 10 years and older. The second administration of the therapy has demonstrated an excellent safety and tolerability profile, with no adverse effects observed. The dogs are currently in a follow-up period expected to conclude in January 2026.
Genflow’s SIRT6 gene therapy leverages a variant associated with longevity, aiming to improve healthspan, vitality, and lifespan in companion animals. The company is advancing its animal health initiative toward the next stage of clinical evaluation and partnership development.
This development underscores the robustness of Genflow’s gene therapy platform and its potential applicability beyond human health. The company remains committed to creating value through innovation and collaboration in the emerging field of genetic longevity therapeutics.
